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THE EPIDEMIOLOGY OF GERM-CELL
TUMOIJRS OF CHILDHOOD
J. M. BIRCH, H. B. MARSDEN and R. SWINDELL
Department of Epidemiology and Social Oncology,
Christie Hospital, Royal Manchester Children's
Hospital, and Department of Medical Statistics,
Manchester.
Data on 135 germ-cell tumours included in
the Manchester Children's Tumour Registry
between 1954 and 1978 have been analysed.
Histological sections of all tumours were re-
viewed and where appropriate original diagnoses
revised in the light of current knowledge. The
distribution of histological types was as follows:
73 benign teratomas, 30 yolk-sac tumours, 13
germinomas, 4 malignant teratomas, 2 terat-
omas of uncertain behaviour, 1 gonadoblastoma
and 12 tumours of mixed histological type. Age
at onset varied with site and histology. Prog-
nosis was found to depend on site as well as
histology. All intracranial tumours were fatal
and presence of yolk-sac elements at any site
indicated a poor prognosis. There was a signifi-
cant excess of females. Germ-cell tumours form
the only group of childhood neoplasms in which
there is a female predominance; an excess of
males is usual.
A search of the clinical notes for associated
pathology revealed an excess of congenital
anomalies. Two patients developed second
malignant tumours which were thought to be
radiogenic.
A cusum plot of the incidence each year re-
vealed a statistically significant increase in yolk-
sac tumours. In view of the probable pre-natal
origin of this and other germ-cell tumours,
additional data were collected on the maternal
obstetric history, including events during the
relevant pregnancy. Preliminary analyses indi-
cate an excess of stillbirths and congenital
abnormalities in other offspring ofthese mothers.
Data on maternal illness, drug-taking during
pregnancy and birth trauma were equivocal. It
is considered that these factors may be of
aetiological significance and further studies are
planned.
THE PROBLEM OF INTRODUCING A
SINGLE PROMUTAGENIC LESION
INTO DNA
R. SAFFHILL
Paterson Laboratories, Christie Hospital and Holt
Radium Institute, Manchester
It is established that 06-methylguanine and
04-methylthymine, produced by the action of
carcinogenic methylating agents, are promuta-
genic lesions in DNA. Attempts to incorporate
the former base into newly synthesized DNA
have not been successful: one reason for this
may be that the nucleoside is rapidly degraded
in vivo, since crude rat cytosol extracts rapidly
demethylate the compound (O'Connor & Saffhill,
Chem. Biol. Interact., in press). Adenosine
deaminase has been implicated as being respon-
sible for this demethylation. In these studies
04-methylthymidine (04-MedT) was found to be
stable to the action of the rat cytosol extracts
and when injected into rats the compound was
excreted largely unchanged.
The effect of 04-MedT upon cells in culture
has been investigated. There was no evidence
of toxicity when the compound was present in
the cultures at concentrations up to 10-2M for
up to 7 days. When [3H]-labelled 04-MedT
was added to the cultures, incorporation into
DNAwas detected by the presence ofthelabelled
nucleoside in DNA extracted from the cells and
then enzymatically degraded.
CHRONIC ADMINISTRATION OF N-
NITROSAMINES ENHANCES THE RE-
MOVAL OF 06-ALKYLGUANINES FROM
RAT LIVER DNA IN VIVO
G. P. MARGISON1, A. W. CRAIG1, H. BRESIL2,
N. CURTIN3, K. SNELL3 and R. MONTESANO2
1PatersonLaboratories, Manchester, 2lnternational
Agencyfor Research on Cancer, Lyon, France, and
3Department of Biochemistry, University of
Surrey, Guildford
Administration of dimethylnitrosamine
(DMN) or diethylnitrosamine (DEN) to rats
results in the formation of various alkylated
bases in DNA. Of these, 06-alkylguanines
(06-AG) appear to be enzymically removed from
rat liver DNA in vivo, whereas others such as
3-alkyladenines (3-AA) and 7-alkylguanines
(7-AG) do not. Chronic administration of low
doses ofDMN or DEN increased the capacity of
the liver to remove 06-AG, as determined after
a subsequent dose of the corresponding radio-
labelled nitrosamine. Thus, 12 h after adminis-
tration of [14C]-DMN (2 mg/kg) to rats given
unlabelled DMN (2 mg/kg/day) by stomach tube
on weekdays for 9 weeks, there was 75% less
06-methylguanine in liver DNA than in that of
control animals which received only [14C]-DMN
(Montesano et al. (1979), Cancer Res., 39, 1798).
Similarly, 12 h after administration of [14C]-
DEN (10 mg/kg) to rats given unlabelled DEN
(equivalent to 10 mg/kg/day) in the drinking
water for 5 weeks, there was 63% less 06-ethyl-
guanine in liver DNA than in that of controls
given [14C]-DEN. In addition, the chronic DEN
treatment enhanced the removal of 06-methyl-
guanine produced by a single dose of [14C]-
DMN (2 mg/kg). In all cases, the levels of 3-AA
and 7-AG indicated that the effect was specific
for 06-AG. These results suggest that the system
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for removal of 06-AG from DNA in rat liver can
be induced by chronic exposure to low levels of
alkylating agents.
REMOVAL OF METHYLATED PURINES
FROM CHINESE HAMSTER LIVER DNA
AFTER SINGLE OR MULTIPLE DOSES
OF DIMETHYLNITROSAMINE
G. P. MARGISON, J. A. SWINDELL, C. H. OCKEY
and A. W. CRAIG
Paterson Laboratories, Christie Hospital and Holt
Radium Institute, Manchester
Dimethylnitrosamine (DMN) has been found
to produce a high incidence of liver tumours in
Chinese hamsters after a single dose of 20 mg/
kg. Using radiolabelled DMN it was found that
the highest level of DNA methylation occurred
in the liver, followed by the kidney (20-1% of
the liver), lung (18-2%), oesophagus (11.2%)
and heart (4-9%). Methylation was detected in
other organs including the brain (0.6% of the
liver). These values reflect the relative capacity
of the various organs to metabolize DMN to a
methylating species.
The levels of 7-methylguanine (7-MeG) and
the promutagenic lesion 06-methylguanine (06-
MeG) in liver DNA have been measured up to
48 h after a single dose of DMN. WVhile the level
of 06-MeG remained constant, there was a rapid
loss of 7-MeG, indicating an enzymic repair
process. These results are very similar to those
obtained for the Syrian hamster, in which DMN
is also a hepatocarcinogen (Margison et al. (1976)
Biochem. J., 157, 627). Induction ofliver tumours
in hamster by DMN may therefore be the result
of the high level of DNA methylation combined
with the inability to remove 06-MeG from DNA.
48 h after administration of [14C]-DMN (3.5
mg/kg) to Chinese hamsters given DMN (3.5
mg/kg) once weekly for 8 weeks there was 77%
more 06-MeG in liver DNA than in that of con-
trol animals receiving only [14C]-DMN. There-
fore, unlike the rat (Montesano et al. (1979) Can-
cer Res., 39, 1798) the ability ofthe hamster liver
to remove 06-MeG from DNA is reduced by
chronic administration of DMN. It remains to
be established whether there is a relationship
between these effects and tumorigenesis, since
chronic DMN treatments are hepatocarcinogenic
in both rat and Chinese hamster.
ENHANCED REPAIR OF 06-METHYL-
GUANINE FOLLOWING CHRONIC EX-
POSURE TO ACETYLAMINOFLUORENE
J. D. BUCKLEY, P. J. O'CONNOR and A. W.
CRAIG
Paterson Laboratories, Christie Hospital and Holt
Radium Institute, Manchester
The interplay of environmental factors may
be relevant to the induction of cancer in man.
We have investigated the effects of two chemic-
ally different carcinogens in a rat-liver system.
The results indicate that exposure of male
Wistar rats to a dietary regimen containing
0.06% acetylaminofluorene (AAF) does not
affect the capacity of the liver to metabolise
dimethylnitrosamine (DMN). Furthermore, after
a pulse of DMN the initial level of alkylation in
DNA of various tissues of AAF-pretreated rats
was broadly similar to that in control rats.
In AAF-pretreated rats, however, the repair
of 06-methylguanine in liver DNA was en-
hanced. This effect was clearly seen at early
times after administration of DMN at doses of
9, 5-5 or 1 mg/kg. After 5 h the ratios of 06-
methylguanine to 7-methylguanine were de-
creased 2-3-fold in treated rats when compared
to relevant controls, indicating the specific loss
of this product. The results show that pretreat-
ment with one carcinogen can induce repair of
lesions produced by another chemically different
agent. Such an effect might be ascribed to either
the induction of a general repair mechanism, or
possibly to the formation of small amounts of
an AAF-adduct at the 06-position of guanine in
DNA, as recently demonstrated for another
aromatic amine, oc-naphthylamine (Kadlubar et
al. (1978) Cancer Res., 38, 3628).
OXIDATIVE METABOLISM OF NICO-
TINE BY CIGARETTE SMOKERS SUF-
FERING FROM CANCER OF THE
URINARY BLADDER, AND OTHER
DISEASES
A. R. HIBBERD, A. E. KLEIN and J. W. GORROD
Pharmacy Department, Chelsea College, Univer-
sity of London
Gorrod et al. (J. Natl Cancer Inst. (1974) 52,
1421) reported a significantly increased ratio
(compared with controls) ofcotinine to nicotine-
F'-N-oxide, which arise by ac-C and N-oxidation
respectively, in 24h urines of smokers with
cancer of the urinary bladder. Therefore a study
of cigarette smokers suffering from urinary
bladder cancer and various other conditions was
thought necessary, to determine whether the
raised ratio was a phenomenon unique to the
former condition.
Urine samples were analysed for nicotine,
nicotine-l'-N-oxide and cotinine (Beckett et al.,
J. Pharm. Pharmacol. (1971) 23, 55S). Because
a decrease in the metabolite ratio was reported
with increasing patient age (Klein & Gorrod,
Eur. J. Drug. Metab. Pharmacokin. (1978) 1, 51)
age-matching of control groups was used in this
study. Disease groups studied were (a) bladder
cancer, (b) various other cancers, e.g. of breast,
ovary, cervix, lung, prostate, etc., (c) bronchitis,
(d)genito-urinary non-cancerous and (e) non-
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cancerous non-genito-urinary. Only the bladder
cancer group exhibited a significantly higher
(P < 0.02) mean ratio (4.08) than its controls
(mean ratio 1.71). Ratios > 4 0 occurred fre-
quently in this condition. Amongst all other
disease groups ratios > 4.0 occurred rarely and
not at all in controls. A significantly raised mean
ratio was a prominent feature in the bladder
cancer groups and was associated with reduced
flavoprotein-mediated production of nicotine-
1'-N-oxide.
Work supported by grants from Cancer
Research Campaign.
EXPOSURE OF SCHOOL POPULATIONS
TO SUSPECTED CARCINOGENIC SOL-
VENTS
F. DEWHURST and W. M. CASSELLS
Life Sciences, Leicester Polytechnic
Science teachers from 54 schools in Southern
England in 1974-5 gave information on their
usage of volatile carcinogens. The percentage
usage of benzene was >monthly 1-8, <monthly
70 4, "never" 18-5, of chloroform > monthly
14-8, < monthly 72-2, "never" 5.6, and ofcarbon
tetrachloride > monthly 27-8, <monthly 59 3,
"never" 9-3. ("No replies" making upthe total to
100.) About one fifth of laboratories smelt ofthe
solvents during use.
In a more detailed nationwide study of 246
schools in mid-1976, the usage of benzene was
>monthly 8-1, <monthly 50.0, "never" 39-8,
of chloroform was >monthly 17.0, <monthly
69-5, "never" 11-8 and of carbon tetrachloride
>monthly 32-1, <monthly 56 1, "never"
10-6%. Reports of usage of benzene, chloroform
and carbon tetrachloride "only in the open
laboratory" were 17, 51 and 52, "only in fume
cupboards" were 50, 24 and 23 and "in both"
58, 114 and 120 respectively. The laboratory
was reported as smelling of benzene, chloroform
and carbon tetrachloride during open laboratory
use in 55, 123 and 118 cases and during fume
cupboard use in 13, 30 and 29 cases respectively.
The odour-detection thresholds (Patty (1963),
Indust. Hygiene and Toxicology, Vol. 2, New
York: Interscience) are benzene 100 pts/106,
chloroform 200 pts/106 and carbon tetrachloride
80 pts/106, greatly exceeding TLV levels.
These data are disturbing in the light of
Capurro's observations (1976, Lancet, ii, 253)
linking solvent-vapour exposure with a high
incidence of lymphoma and pancreatic tumours,
and of British, Swedish and American studies
on chemists showing high levels of lymphoma,
leukaemia and pancreatic tumours (Searle et al.
(1978), Br. J. Cancer, 38, 192).
DNA STRAND BREAKS IN YOSHIDA
CELLS DIFFERING IN SENSITIVITIES
TO METHYLENE DIMETHANE SUL-
PHONATE (MDMS) AS ASSAYED BY
THE ALKALI UNWINDING/HYDROXY-
APATITE TECHNIQUE
F. J. CARR and B. W. Fox
Paterson Laboratories, Christie Hospital and Holt
Radium Institute, Manchester
The incidence of DNA strand breakage was
examined after treatment of cultured cells de-
rived from rat Yoshida sarcomas differing in
relative sensitivities to the alkylating agent,
MDMS. The hydroxyapatite chromatographic
technique of Ahnstrom & Erixon (1973, Int. J.
Radiat. Biol., 23, 285) has been adapted for these
measurements in exponentially growing cells.
Initially, possible artefacts due to culture con-
ditions were eliminated. Low levels of breaks
were induced at similar levels in the two cell
lines after 30min MDMS treatment, and these
were increased for increasing dose. Slow re-
joining was observed over 2 h and to equal
extents in these cell lines. The patterns of DNA
synthesis after drug treatment were assessed in
these cells in detail. At equal doses a much
larger depression ofDNA synthesis was detected
in the sensitive line than in the resistant line.
At doses giving similar cell survival, the initial
depression was similar, but at times up to 6 h
there appeared to be more recovery of DNA
synthesis in resistant than in sensitive cells.
Using the measured levels of DNA synthesis,
different periods of pulse label were given 1 h
after drug treatment in order to give similar
levels of DNA synthesis in all samples, and the
ligation of this newly synthesized DNA was
followed using the hydroxyapatite technique.
At equal doses, the labelled DNA appeared to be
ligated more fully in resistant than sensitive
cells, providing evidence for defective post-
replication repair in sensitive cells.
MEASUREMENT OF THE UPTAKE AND
INTRACELLULAR LOCALIZATION OF
DAUNORUBICIN USING FLOW MICRO-
FLUORIMETRY
A. GARNER and B. W. Fox
Paterson Laboratories, Christie Hospital and Holt
Radium Institute, Manchester
Uptake of daunorubicin (DnR, NSC-82151)
by wild-type Yoshida cells in culture can be
measured from the laser-excited emission of the
drug in a flow system (Bio/Physics 4800A). The
rate and extent of drug uptake increases with
the concentration of the drug in the culture
medium. At concentrations above 10 ,uM there
is a build-up of cell debris due to the rapid and
direct action of the drug, which may be dis-
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tinguished from intact cells on the basis of
particle size.
There is a large decrease in laser-excited
emission from DnR-treated cells which have
been fixed and treated with RNase. The
emission is too weak to distinguish any cell-
cycle pattern of staining, which might have been
expected since DnR is known to intercalate in
double-stranded DNA (Di Marco et al. (1976),
Cancer Res., 36, 1962). The effects of incubation
of cells with DnR and subsequent staining with
acridine orange (AO) and ethidium bromide in
flow microfluorimetry experiments was tested.
The observations show that the binding of these
drugs is affected by DnR, but in different ways
which depend on the association constants of
the dyes with DNA.
The ratio of red to green fluorescence from
AO increases with the time of incubation of the
cells with DnR, which indicates that DnR treat-
ment of cells affects the ratio of double- and
single-stranded DNA available for AO binding.
This method was used to measure uptake of
DnR into cell nucleoprotein, and the results
were compared with DnR uptake measured by
extraction into chloroform.
MEASUREMENT OF MELPHALAN AND
CHLORAMBUCILAND THEIRMETABO-
LITES BY A SINGLE HIGH-PRESSUJRE
LIQUID-CHROMATOGRAPHY METHOD
A. G. BOSANQUET, M. HENFREY and E. D.
GILBY
Department of Oncology, Royal United Hospital,
Bath
Measurements of melphalan (M) and chlor-
ambucil (C) at the concentrations found in
plasma during chemotherapy have recently
become possible by high-pressure liquid chroma-
tography (HPLC). However, either a gradient
elution system has been necessary, or measure-
ment of the degradation products of AI (mono-
hydroxymelphalan, MOH, and dihydroxy-
melphalan, M(OH)2) is made difficult by their
close proximity to the solvent front.
We have developed a method which uses an
isocratic elution system suitable for the measure-
ment of M, MOH and M(OH)2 or C and its
metabolite phenyl acetic mustard (PAcM).
Sodium lauryl sulphate (SLS) is used in the
mobile phase as an ion-pair reagent, and dansyl
proline (DP) as an internal standard.
The drug plus added DP is first extracted from
the plasma sample by washing through an
XAD-2 column and eluting with methanol. This
methanol eluate is injected directly on to the
HPLC column and eluted with methanol/water
containing SLS. It has been found that reduc-
tion of the methanol concentration or tempera-
ture causes an increase in all k' values, whereas
a pH change either way, or a reduction in SLS
concentration, reduces the k' of M, MOH and
M(OH)2 markedly and DP slightly, whereas the
position of C and PAcM remain virtually un-
changed.
EFFECT OF LIPOSOME ENCAPSULA-
TION OF ACTINOMYCIN-D ON ITS
THERAPEUTIC EFFICACY
S. B. KAYE, J. A. BODEN, K. D. BAGOSHAWE and
B. E. RYMAN
Departments of Medical Oncology and Bio-
chemistry, Charing Cross Hospital, London
Liposomes (phospholipid vesicles) are capable
of prolonging the plasma clearance, modifying
the tissue distribution and enhancing the in
vitro activity of cytotoxic agents, and have
therefore been proposed as drug carriers. We
have compared the efficacy of actinomycin D
(AD) encapsulated in small cationic liposomes
with thatoffree drug, in acombinedtherapeutic-
toxicity study. The model used was the Ridgway
osteosarcoma (ROS) maintained by serial pass-
age in AKR mice.
For free AD the minimum effective dose
(MED the dose which inhibited tumour growth
to 10% of control tumour weight) was 0 3 mg/
kg, and the LD50 was 0-8 mg/kg. In contrast,
with i.v. doses up to 8 mg/kg ofAD encapsulated
in liposomes, neither the MED nor the LD50
have been reached. The maximum tumour-
growth inhibition was 68% of control tumour
weight, whilst survival of mice treated with
8 mg/kg of entrapped drug was 83%.
These results indicate that, despite a con-
siderable delay in plasma clearance (the 5h
plasma level of AD was 37-fold greater for en-
trapped than for free drug) the activity of AD
encapsulated in liposomes in both host and
tumour tissues is markedly reduced. This may
partly be due to failure ofdrug uptake, since the
peak ROS tumour AD concentration (expressed
as percentage ofinjected dose per g oftumour at
24h) was 6-0% ± 0 5(mean +s.e.) forfreeAD,and
2.0%+0-2 for entrapped AD. Further studies
should determine whether liposome encapsula-
tion of cytotoxic drugs may prove more useful
for the treatment of drug-resistant tumours, or
for those drugs whose activity is enhanced by
delayed plasma clearance.
EFFECT OF HYPERTHERMIA ON THE
PHAGOCYTIC ACTIVITY OF TUMOUR-
BEARING ANIMALS
S. A. SHAH and J. A. DICKSON
Cancer Research Unit, University Department of
Clinical Biochemistry, Royal Victoria Inftrmary,
Newcastle upon Tyne
Previous work has shown that, following
curative local heating of the rabbit VX2 carcin-
oma, tumour regression resulted in host cure,
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with anl increase in both cellular and humoral
iinmune competence (Shah & Dickson (1978)
Cancer Res., 38, 3518). This work has beeni ex-
tended in the rabbit system and in a rat MAC7
sarcoina inodel wxith a viewx to determining the
role of inacrophages in tumnotur regression
followTing curat,ive hyperthermia.
The phagocytic index (K) was deterinined at
7-10-day intervals by ineasuiring the rate of
clearance of colloidal carbon (8 ing/100 g body
wt) froin blood. Serum lysozyine levels, which
have been claimed to reflect macrophage activity
in vivo, were determined by a turbidonetric
inethod.
In ulntreated rabbits and rats, progressive
tumnour growth was accomnpanied by a 5-fold
increase in K and a 3-fold increase in serum
lysozyme levels. After curative heating of intra-
musctular VX2 tuinouirs (15-20 ml, 47-50'C/30
mni) and the AIC7 sarcoma ini the foot of rats
(1-1-3 ml, 43°C/2 h), animals in which carbon
clearance wNas sequientially tested showed a
decreased tuimour cuire rate, from 70% to 17%
in rabbits and fromn 100% to 50% in rats. Cured
aninnals showed no decrease in elevated serumn
lysozymne. Tumour recurrence and death of the
animnals was associated with K and serumrn lyso-
zyrne levels comparable to those in untreated
tumoour-bearing animals. The lysozyme content
of untreated MNC7 sarcomas increased with in-
crease in tumiiour mass, whereas the enzymne
content of tumrnouirs decreased significantly over
7 days' curative heating.
The results stuggest that K anid sertumn lyso-
zymne levels may be related to host tumiour
bturden, but ca,nnot be used to monitor tuimour
regressionl.
NATURAL IMMUNITY IN RATS DE-
VELOPING SPONTANEOUS TUMOURS
G. H. FLANNERY and C. (C. BRooKs
Cancer Research Car7npaiqn Laboratories, Univer-
situy of Nottingham.
A small proportion of animnals in an inbred
colony of WAB/Not rats spontaneously develop
tumnour-s in the breast, or kidney. The spon-
taneouis cytotoxicity of spleen cells fromn both
tumour-bearing and age-, sex- and parity-
matched control animals has been measured in
a 61i release assay rising target cells derived fromn
a syngen-eic methylcholanthrenie-induced sar-
coma. The natural cytotoxic activity of n-ormal
aniimals in the saine age and parity range as the
spontaneouis breast, tutmour bearers has pre-
viously been shownr to be coinparable with that
of young (8 12-week) aninals, and to be
mediated by non-phagocytic, non-adherent,
non-T, inon-B cells bearing Fe receptors. Spoirn-
taneous tumnotur-bearers exhibited levels of
cytotoxicityr occasionally lower than that of
55
controls on a cell-for-cell basis, but at least as
high as controls when total splenic lytic units
were considered. Variations in reactivity were
apparently unrelated to age, parity or tumour
type. Thuis, the development of spontaneous
tumours in this system is not associated with
either increased or decreased splenic natural
immunity, a finding of considerable importance
in view of the possible role or natural immunity
in imnmune surveillance.
BCG-INDUCED AUGMENTATION OF
NATURAL CYTOTOXICITY IN THE RAT
Mr. R. POTTER and A. MOORE
Department of Immunology, Paterson Labora-
tories, Ch,ristie Hospital and Holt Radium Insti-
tute, 1Hanchester
In the norinal Wr/Not rat, natural (spon-
taneous) cytotoxicity in the peritoneal cavity is
interinediate (3.4 lytic units/106 cells) between
that, of spleen (10-6 lu/106 cells) and lymph node
( <1 lI/106 cells). I.p. injection of BCG (Glaxo)
induced a significant dose- and time-dependent
augmentation of cytotoxicity against the human
erythroleukaemic cell line, K562, as determined
by 5iCr release from pre-labelled target cells.
Stimrulation was mnaximal 4 days after rats were
inoculated w\%ith 7 mg (dry wt) BCG, and heat-
killed (1 h at 80C) organisms were no less
effectixve than viable preparations. A a-fold
increase in cytolytic activity was observed in
BCG-induced exudates compared with the
unstimulated population, determined at several
E :T ratios. Under these conditions, activity in
the peritoneal cavity (17-5 1r/106 cells) exceeded
that of spleen cells (12-7 lu/106 cells) which, like
lymphnode cells, showed little deviation from
their respective levels in unstimulated hosts.
Deployment of various fractionation procedures
indicated that the augmented cytolysis was
attributable to more than one cell type, but that
a mnajor component was similar to natural killer
(NK) cells in untreated hosts. Augmentation of
their activity appears to be a property of
diverse agents which induce strong nonspecific
inmunity, and this effect may be linked to the
induction or release of interferon. As such, these
data could be relevant to current immuno-
therapeutic trials uising these agents, including
interferon it,self.
COMPARISON OF LYMPHOID CELLS
INFILTRATING TUMOURS GROWING
PROGRESSIVELY OR UNDERGOING
IMMUNOTHERAPY - INDUCED RE-
GRESSION
R. A. ROBINS, G. R. FLANNERY and R. W.
BALDWIN
Cancer Research Campaign Laboratories, Univer-
sity of Nottingham
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Regression of a methylcholanthrene-induced
transplanted rat sarcoma has been obtained
after treatment with an inoculum of sarcoma
cells in admixture with BCG. Previous studies
have shown that this regression is accompanied
by a marked lymphoid infiltration. Lymphoid
cells have been separated by nylon-column
filtration from both progressively growing and
regressing tumours 10 days after inoculation,
and these cells have been compared in short-
term (6h) 57Cr-release, and long-term (60h)
[74Se] selenomethionine-uptake cytotoxicity
assays, and for their capacity to control tumour
growth in vivo in Winn-type assays. Although
the yields of host cells from regressing tumours
are greater than those from progressing tumours,
no consistent quantitative or qualitative differ-
ences between the lymphoid cells from the two
types of lesion have so far been detected in the
in vitro or in vivo tests. These results argue
against the generation of a new type of effector
cell induced by the immunotherapy, and suggest
that factors controlling extravasation and accu-
mulation of lymphoid cells within tumours may
be important in immunotherapy-induced tumour
regression.
NATURAL CYTOTOXICITY IN MAN:
LOW SUSCEPTIBILITY OF FRESHLY
ISOLATED TUMOUR CELLS TO LYSIS
B. M. VOSE and M. MOORE
Department of Immunology, Paterson Labora-
tories, Christie Hospital and Holt Radium Insti-
tute, Manchester
Blood lymphocytes from healthy donors and
cancer patients have been tested for cytotoxic
potential against freshly isolated ltng tumour
cells and the K562 cell line. While the majority
showed high reactivity for the cell line, only very
low levels of cytotoxicity could be detected
against the tumour targets, except in 6/75 cases.
In many individuals, cells were completely re-
fractory under the conditions used (4h 51Cr
release at an effector:target ratio of 50:1). This
low susceptibility to lysis was confirmed in cold-
inhibition assays, in which fresh tumour cells
showed minimal capacity to interfere with
killing of K562 targets. By contrast, K562 cells
uniformly blocked cytotoxicity. These data
would suggest that NK effectors can play only a
minor role in protection against established
human neoplasia. However, the susceptibility of
freshly isolated tumour targets may not be so
low as to be biologically irrelevant. By boosting
levels of NK by treatment with interferon, and
extension ofthe assay time to 18 h, higher levels
of NK-mediated lysis could be detected.
ANTIBODY INDUCTION BY 3-METHYL-
CHOLANTHRENE (MCA)-TREATED
SPONTANEOUS TUMOUR CELLS
AGAINST OTHER NON-MCA-INDUCED
TUMOURS
J. G. REEVE and M. J. EMBLETON
Cancer Research Campaign Laboratories, Univer-
.sity of Nottingham
It has previously been shown that rat embryo
cells treated in vitro with MCA elicit antibodies
in syngeneic rats which react specifically against
certain established MCA-induced sarcomas, in-
dicating the acquisition of new antigens cross-
reacting with those sarcomas. We now report
that antibodies can similarly be elicited by
MCA-treated malignant cells, and that they may
react against tumours not induced by MCA.
Cells of a non-immunogenic spontaneous mam-
mary carcinoma (Sp15) were treated for 18 h
with MCA (10 Htg/ml) in 0.5% acetone, or
acetone alone, and washed x 6. Syngeneic rats
were immunized with these cells and their sera
were tested for membrane immunofluorescence
against various types of established tumours.
Sera from rats immunized against MCA-treated
Sp15 cells were positive against an immunogenic
spontaneous mammary carcinoma (Sp4) and an
aminoazodye-induced hepatoma (D192A). Sera
from acetone-treated Spl5 cells were negative,
and this confirms the previously demonstrated
inability of Tumour Spl5 to induce antibody
responses in syngeneic rats. The results suggest:
(a) that the induction of new antigenic speci-
ficities by MCA is not necessarily related to the
process of malignant transformation, and (b)
that the antigens themselves are not carcinogen-
specific.
ANTIGENIC CROSS-REACTIVITY BE-
TWEEN BCG AND RAT TUMOUR CELLS
M. V. PIMM
Cancer Research Campaign Laboratories, Univer-
sity ofNottingham
The guinea-pig hepatoma Line-10 and human
melanoma cells have been reported to cross-
react antigenically with BCG (Borsos & Rapp
(1973) J. Natl Cancer Inst., 51, 1085; Minden
et al. (1974) J. Natl Cancer Inst., 53, 1325, and
J. Immunol. (1976) 116, 1407). In the present
study the cross-reactivity of Line-10 and BCG
has been confirmed, and a series of carcinogen-
induced and spontaneous rat tumours has been
examined for similar shared antigens.
Rabbit antiserum against BCG (DAKO
Immunoglobulins, Copenhagen) reacted in an
indirect-immunofluorescence test with BCG
organisms (Glaxo) and with viable cells in sus-
pension from Line-10 guinea-pig hepatoma, an
aminoazo-dye-induced rat hepatoma (D23), an
MCA-induced sarcoma (Mc106B) and a spon-
820ABSTRACTS OF BACR MEMBERS PAPERS
taneous mammary carcinoma (Sp22). Anti-
Forsmann serum raised in rabbits against sheep
red blood cells (Wellcome Reagents) also re-
acted with rat and guinea-pig tumour cells, but
failed to react with BCG organisms, indicating
that the component shared netween BCG and
malignant cells is not classical Forsmann anti-
gen. Absorption ofanti-BCG serum with Line-10
cells abolished reactivity against both guinea-
pig and rat tumour cells, and anti-BCG antibody
adsorbed to and acid-eluted from Line-10 cells
reacted with Line-10 cells and rat tumour cells,
but not with normal rat cells, indicating com-
mon component(s) between Line-10, malignant
rat cells and BCG.
This, and other reports of cross-reactivity
between BCG and malignant cells, suggests that
the immunotherapeutic effect of BCG may, at
least in part, be due to their shared antigenic
components.
TUMOUR-SPECIFIC ANTIBODY PRO-
DUCTION BY MOUSE MYELOMA-RAT
SPLEEN CELL HYBRIDS
B. GUNN, M. J. EMBLETON and J. G. MIDDLE
Cancer Research Campaign Laboratories, Univer-
sity ofNottingham
Hybrids between P3-NS1 mousemyeloma cells
and spleen cells from rats immune to syngeneic
tumours were prepared by fusion with poly-
ethylene glycol. The tumours used were an
aminoazo dye-induced hepatoma (D23) and a
spontaneously arising mammary carcinoma
(SP4), both of which are able to induce a
specific antibody response in syngeneic WAB/
Not rats. Supernatants from hybrid cells growing
in selective (HAT) medium were tested for anti-
body activity against various tumour and
normal cell targets, using an assay in which
bound antibody was detected with 125J-labelled
sheep F(ab)2 anti-rat IgG. Antibody was de-
tected in 1/38 supernatants from hybrids of
P3-NS1 and Sp4-immune spleen cells, and in
2/76 supernatants from P3-NSI/D23-immune
spleen cell hybrids. Specificity tests showed that
these antibodies were specific for the tumour to
which the spleen-cell donor was immunized.
These results indicate the possibility of prepar-
ing monoclonal antibodies against tumour-
specific antigens using syngeneic spleen-cell
donors, thus avoiding many problems of
specificity and the enforced rigorous selection
associated with the use of xenogeneic spleen-
cell-donors.
PAPAIN SOLUBILIZATION OF RAT
HEPATOMA D23 SPECIFIC ANTIGENS
M. E. EVANS, D. HANNANT, J. G. BOWEN and
M. R. PRICE
Cancer Research Campaign Laboratories, Univer-
sity ofNottingharm
Tumour-specific antigens expressed upon the
aminoazo dye-induced WAB/Not rat hepatoma
D23 are integral plasma-membrane-associated
glycoproteins, being sensitive to papain, which
renders soluble antigenic glycopeptides reactive
with concanavalin A, and of mol. wt 50,000-
60,000. The release of surface components by
papain has been studied in greater detail, using
hepatoma cells metabolically labelled in vitro
with 3H-fucose and 3H-leucine. With increasing
concentrations of papain, under conditions
which do not affect cell viability, the release of
fucose- and leucine-labelled soluble materials
followed similar kinetics, which were also com-
parable to the release/inactivation of WAB/Not
alloantigens as determined by assaying residual
antigenic activity on treated cells by a radio-
isotopic antiglobulin test. Fucosylated com-
ponents displayed a higher mol. wt profile that
leucine-labelled material and - 50% of these
glycopeptides were retained on Sepharose 4B-
con A columns, compared with less than 5% of
leucine-labelled components.
These internally labelled surface components
are being examined for the retention of tumour-
specific antigens by their capacity to bind to
specific immunoadsorbents containing im-
mobilized syngeneic hyperimmune sera, and
preliminary characterization of these columns
using radioiodinated, papain-solubilized D23
antigen indicate that the immunoadsorbents
contain specific antibodies predominantly oflow
affinity for soluble tumour antigens.
LYMPHOCYTE RESPONSE TO PHA AND
ITS RELEVANCE TO CANCER DETEC-
TION
J. A. V. PRITCHARD, J. E. SEAMAN, I. J. KERBY,
T. J. DEELEY and B. H. DAVIES
Immunology Department, Tenovus Laboratories,
South Wales Radiotherapy and Oncology Service,
Velindre Hospital, Cardiff, and Asthma Research
Unit, Sully Hospital, S. Glam.
Recent evidence (Pritchard et al. (1978)
Lancet, ii, 1275) has shown that the successful
operation of the SCM technique (Cercek &
Cercek (1978) Eur. J. Cancer, 13, 903) can be
used to monitor lymphocyte response to PHA,
and that this is dependent upon the sampling
technique of the separated cell population.
Lymphocytes separated from normal and
benign-disease donors and sampled at the
normal interface region (Band 1) of a modified
Ficoll/Triosil gradient (p= 1-081 g/cm3 at
19°C) show characteristic responses to PHA
when assessed by the SCM technique. Lympho-
cytes sampled at the same regions from subjects
with malignant disease exhibit little if any
response to PHA. However, response to PHA
can be characteristically demonstrated for
lymphocytes from patients with malignant
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disease when the region below the normal
gradient interface is sampled (Band 2). A study
of varying sizes of skin cancer has show-n that a
tumour of > 3 mm diameter is necessary for this
phenomenon to occur in the lymphocyte popU-
lation with a resultant PHA response in Band 2
cells. A study of benign and malignant chest
conditions has shown that remarkable dis-
crimination can be obtained between the groups.
THE MODIFIED Clq TEST IN PATIENTS
WITH BREAST CANCER
P. J. DOYLE, R. A. ROBINS, P. J. WEBB, R. WA.
BALDWIN and R. W. BLAMEY
Department of Surgery and CRC Laboratories,
University of Nottingham
A retrospective study using the Clq binding
assay (Zubler et al. (1976) J. Iimmunol., 116, 232)
w as performed on heparinized plasma samples
from patients with breast cancer. A relationship
between the mean levels of binding for patients
in different prognostic groups w%vas demonstrated
(Hoffken et al. (1978) Lancet, i, 672) but wTide
variation in results precluided prediction for
individual patients. To standardize collection
and storage, serum samples were chosen for a
prospective study. Initial tests on serum did not
distinguish between patients and controls. The
addition of heparin to samples increased levels
ofbinding in patients with breast cancer but had
little effect on control samples. Preliminary
resuilts are:
Benign
Young breast
adults disease
Number 12 25
Mean+s.d. 4-82+2-79 8 4t5+ 5 03
Breast
cancer
39
18-12 + 9 47
Pre-operative testing gave raised levels of
binding in 31/39 patients N-ith breast cancer, btit
only 6/25 patients with benign breast disease
(P < 0-001). In cancer patients with raised levels
tested one month postoperatively, 800% of levels
fell to normal. Cancer patients tested 6 inonths
or more postoperatively were divided according
to node stattus. The mean level for node-
negative patients was 8-61 + 4-65, for node-
positive patients 17-70 + 10-91.
These preliminary results suggest that the
modified Clq binding assay is a uisefuil marker in
patients with breast cancer.
CORYNEBACTERIUM PARVUM TREAT-
MENT OF PATIENTS WITH BRON-
CHIAL CARCINOMA: A PROSPECTIVE
CLINICAL TRIAL
H. D. MIITCHESON and J. E. CASTRO
Department of Surgery, Royal Postgraduate
Medical School, Hammersmith Hospital, London
62 patients entered a trial of C. parvum (CP)
treatment for histologically confirmed bronchial
carcinoma not amnenable to operation. Patients
were randomized to CP +radiotherapy or
radiotherapy alone ("controls") with stratifica-
tion for histological type, tunmour size and
spread.
Patient entry:
Localized disease: Squamous CP,19; Con-
trol, 18. Anaplastic CP, 2; Control, 2. Oat-cell
CP,1; Control, 2.
Metastatic disease: Squamouis CP, 11; Con-
trol, 4. Oat-cell CP, 1; Control, 0.
Refused treatment: 2.
MIean age of patients receiving CP was 56-9
years and controls 58-3 years.
Side effects: CP (10 Mg/M2) given by i.v. in-
fusion monthly to a total of 4 caused fever,
malaise, rigors and pyrexia. Pyrexia lasted 6-72
h (inean 10 h) wNith a maximum mean tempera-
ture of 38 7°C. Systolic blood pressure dropped
in most patients, and 3 patients needed treat-
merit; 9 required antiemetics; 2 became con-
fused and 8 had a flu-like illness. 4 patients
refused to cornplete the course; 20 found the
treatment easily acceptable. The remainder had
an initial severe reaction buit stibsequent in-
fusions had less effect.
Preliminary overall patient survival w\Nith
localized disease is:
22 CP
r-
Alive Dead
10 12
22 Controls
Alive Dead
10 12
(14-0 + 1-34) (4-6 + 0.9) (12-3 + 0.9) (3.3 + 0.7)
(inonths + s.d. from start of treatment)
W'e conclude that CP is safe and tolerated by
most patients, but significant prolongation of
survival has not yet been demonstrated.
THE YORKSHIRE TRIAL OF IMMUNO-
POTENTIATION WITH LEVAMISOLE
IN SURGICALLUNGCANCER: FOLLOW-
UP OF 317 PATIENTS TO NOVEMBER
1978
H. MI. ANTHONY, A. J. MNEARNS, AX. K. MASON,
K. MNOGHISSI and D. A. WATSON
Department of Immnunology, Leeds General
Infirmary
Patients undergoing operation for lunig cancer
at 3 centres were ranidomized to levainisole or
placebo treatiment. Treatmeent with 1 tablet
(50 mg) 2-4 times a day (according to body wt)
started 3 days before operation and continuted
3 days a fortnight for 2 years.
Patients on levamisole showed a significant
excess of deaths from cardiorespiratory failure
in the 6 wTeeks after operation. These were
attribtuted to cardiac autoimmune attack, fatal
becauise of the patient's altered pulmonary
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circulation. Later follow-up of the patients will
be reported in terms both of "all deaths" and of
"cancer deaths" in order to detect any advant-
age which levamisole may give to those sur-
viving early hazard. This report concerns
follow-up of all trial patients to 1 year after the
end ofpatient accrual.
THE USE OF SENSITIZED PIG LYMPH-
NODE CELLS IN THE TREATMENT OF
CARCINOMA OF THE OVARY
G. M. TURNER and M. 0. SYMES
Departments of Obstetrics and Gynaecology and
Surgery, University of Bristol
5 patients with carcinoma of the ovary, 4 at
clinical Stage III and 1 at Stage IV, have been
treated by injection of sensitized pig mesenteric
lymphnode cells. In 3 patients the nodes were
immunized against the patient's tumour and in
2 against her skin.
All patients had viable tumour present at the
time of immunotherapy, in spite of the maxi-
mum possible surgery± radiotherapy.
One patient died 12 days after treatment, and
both a pelvic tumour mass and a hepatic
secondary showed evidence of massive haemor-
rhagic necrosis. A further patient died 2
months after treatment, extensive pelvic and
vaginal tumour deposits (present at the time of
treatment) having completely disappeared. One
patient had temporary relieffrom ascites forma-
tion lasting 2 months, and a further patient had
a remission lasting 4 months, during which she
lived a normal life and gained weight.
The fifth patient had a right pleural effusion
associated with right pleural tumour deposits.
She received pig cells by intrapleural and i.v.
injection, and is alive and free from tumour
recurrence 4 years and 8 months later.
(Abstracts of the BASO members papers are appearing separately in Chemical
Oncology)
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